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Abstract
Background: The aim of this study was to assess the dose to the humeral head planning risk volume with the
currently used high tangential fields (HTF) and compare different planning techniques for breast radiotherapy
including axillary level I and II lymph nodes (PTVn) while sparing the humeral head.
Methods: Ten patients with left-sided breast cancer were enrolled in a planning study with 16 fractions of 2.66 Gy.
Four planning techniques were compared: HTF, HTF with sparing of the humeral head, 6-field IMRT with sparing of
the humeral head and VMAT with sparing of the humeral head. The humeral head + 10 mm was spared by
restricting V40Gy < 1 cc.
Results: The dose to the humeral head was too high with HTF (V40Gy on average 20.7 cc). When sparing the
humeral head in HTF, PTVn V90% decreased significantly from 97.9% to 89.4%. 6-field IMRT and VMAT had a PTVn
V90% of 98.2% and 99.5% respectively. However, dose to the lungs, heart and especially the contralateral breast
increased with VMAT.
Conclusions: The humeral head is rarely spared when using HTF. When sparing the humeral head, the 6-field IMRT
technique leads to adequate PTV coverage while not increasing the dose to the OARs.
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Background
In case of limited metastatic sentinel node involvement
the choice between axillary dissection or breast irradi-
ation with or without axillary radiotherapy does not
seem to make much difference in terms of regional re-
lapse and survival. Both treatment modalities lead to
sporadic regional recurrences [1, 2]. Irradiated volume
and toxicity are related and this relationship plays a role
in the choice of treatment.
Several studies reported decreased mobility of the
shoulder after radiotherapy [1, 3–6]. The AMAROS trial
compared radiotherapy and surgery of the axilla for pa-
tients with a positive sentinel lymph node [1]. Both
groups reported decreased arm mobility with a worse
quality of life for patients that underwent radiotherapy
treatment compared to patients with an axillary lymph
node dissection. It is suggested that irradiation of the
shoulder tissue leads to decreased mobility. The ESTRO
consensus guideline for target delineation for elective
breast and nodal radiotherapy establishes the humeral
head and connective tissues 10 mm around it as plan-
ning risk volume (PRV) [7].
Tangential fields are widely used for breast radiother-
apy [8–11]. Modified high tangential fields (HTF) have
been proposed to ensure coverage of the level I and II
lymph nodes [12, 13]. Ohashi et al. extended the tangen-
tial fields in the cranial and posterior direction to
include level I—III lymph nodes [13], while Alco et al.
extended the cranial and posterior border to include
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level I and II lymph nodes [12]. IMRT techniques for
breast radiotherapy emerged over the past years due to
the improved dose homogeneity and target coverage
compared to HTF [9, 14–16]. Dogan et al. concluded
that sparing of the humeral head while maintaining tar-
get coverage is best achieved with a 9-field IMRT tech-
nique for the whole breast with internal mammary
nodes, supraclavicular and axillary lymph nodes [14].
More recently, VMAT techniques have been explored
for breast radiotherapy due to the improved dose homo-
geneity and target coverage compared to HTF and IMRT
for whole breast radiotherapy. While reducing hotspots
(dose > 107%) in the PTV and high doses in organs at
risk (OAR), larger low dose regions in OARs have been
reported [15, 17–19]. Osman et al. found improved tar-
get coverage, conformity and reduced lung doses when
comparing VMAT with 3D conformal radiotherapy
plans for the breast, internal mammary node and peri-
clavicular lymph nodes [15]. However, the average dose
to the contralateral breast increased when using VMAT.
The aim of this planning study was to assess the dose
to the humeral head PRV with the currently used HTF.
If this dose is too high, the influence of the humeral
head sparing on the coverage of target volumes with
HTF is determined. Finally, the optimal technique for
humeral head sparing in elective breast radiotherapy in-
cluding level I and II lymph nodes will be determined by
comparing different planning techniques.
Methods
Patients and equipment
Ten consecutive patients with left-sided breast cancer
previously treated at our institute were enrolled in a
planning study performed in Pinnacle3 (v9.8; Philips).
This patient dataset reflects the variations in the irradi-
ated anatomy in our patient population well. Treatment
planning of left-sided breast radiotherapy is more chal-
lenging due to the proximity of the heart to the treat-
ment volume and increased heart dose compared to
right-sided breast radiotherapy. Voluntary breath hold is
state of the art for left-sided breast radiotherapy to
reduce the heart dose [20] and was used during treat-
ment of all ten patients.
The planning CT was acquired with a Big Bore CT
scanner (Philips, Best, The Netherlands) and a slice spa-
cing of 3 mm. Patients were scanned on a breast board
with both arms resting in an arm support above the
head. CTV and GTV were contoured by the radiation
oncologist according to the ESTRO guidelines [7] and
expanded with a 7 mm PTV margin while excluding the
skin with a margin of 7 mm and the lungs without an
additional margin (see Fig. 1). The heart was contoured
according to Feng et al. [21].
Treatment planning techniques
In this planning study, we compared four techniques:
 High tangential field (HTF)
 HTF with sparing of the humeral head
 6-field IMRT with sparing of the humeral head
 VMAT with sparing of the humeral head
The humeral head PRV (hh+10) was spared by
restricting V40Gy < 1 cc for the last three techniques.
Data on the critical dose the humeral head is scarce and
we chose to follow the recommendation of Dogan et al.
who employ a maximum dose of 40 Gy for the humeral
head in their planning study [14]. Treatment plans were
obtained with the inverse planning tool and optimization
was achieved by decreasing the dose to the OARs (lungs,
heart and contralateral breast) as low as possible while
maintaining a PTVp (breast) V95% ≥ 97% and PTVn
(level I and II lymph nodes) V90% ≥ 95%. V107% was
limited to 2% of the target volume. The initial set of
planning objectives is given in Table 1.
All techniques were planned with 6 MV photon
beams. For the HTF, the cranial and posterior border of
the tangential fields was extended to include PTVn. The
maximum number of segments was 8 with a minimum
area of 9 cm2 and a minimum of 4 MU per segment.
The collimator angle was 0 degree. These setting were
the same for HTF with and without sparing of the
Fig. 1 Axial, sagittal and coronal slices of the planning CT of patient 2. PTVp (primary) in red, PTVn (level I and II lymph nodes) in turquoise and
humeral head + 10 mm in green
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humeral head. The plan was optimized with the initial
objectives of Table 1 to fulfil the previously mentioned
evaluation criteria for PTV coverage and minimized
OAR doses. For HTF with sparing of the humeral
head, the leaves of the 10 mm MLC were then manu-
ally closed to exclude hh+10 and reduce the dose to
the humeral head and surrounding tissue.
The 6-field IMRT technique consisted of two high
tangential fields and four additional fields (at around
330, 20, 80 and 170 degrees, see Fig. 2) to ensure
proper coverage of the cranial part of the breast and
the lymph nodes. The two tangential fields were the
same fields as in the HTF planning without sparing
of the humeral head and administered 60% of the
MU. The caudal border of the four additional fields
was set 1 cm below the sternoclavicular joint and the
isocentre was placed in that slice. The minimal cra-
niocaudal dimension of the additional fields was
3 cm. The maximum number of segments was 20
with a minimum area of 9 cm2 and a minimum of 4
MU per segment. The collimator angles of the high
tangential and additional fields were 0 and 90 degree,
respectively.
The fourth technique was a VMAT dual arc from
around 310 to 180 degrees with control points every 4
degrees. In the optimization parameters, the maximum
delivery time was 60 s per arc. The minimum segment
area was 6 cm2 and the collimator was rotated 10 degree
to minimize tongue-and-groove effects.
Plan evaluation
Dose parameters were recorded for each plan. V90% and
V95% of PTVp and PTVn were obtained, as well as the
average dose to the lungs, heart, the contralateral breast
and the V40Gy of hh+10. The conformity indices CI95%
and CI90% were calculated as the ratio between the vol-
ume of the 95% or 90% isodose and the total PTV. Dose
parameters of two planning techniques were tested for
statistical significance with a paired two-tailed Wilcoxon
signed rank sum test in Excel. It was corrected for mul-
tiple testing with the Bonferroni method (n = 4) and dif-
ferences were considered significant when p ≤ 0.0125. In
addition, the volume overlap between hh+10 and the
PTVtotal was measured. In a sub-analysis, it was investi-
gated whether the overlap between these two structures
could indicate which patient benefits from a humeral
head sparing technique and which could be treated
properly with the current standard of HTF (see
Appendix).
Results
HTF resulted in an average PTVp V95% of 97.8% and an
average PTVn V90% of 97.9% (Table 2). When sparing
the humeral head, this decreased to 97.2% (p = 0.02
compared to HTF) and 89.4% (p ≤ 0.01 compared to
HTF), respectively. With the additional fields of the 6-
field IMRT technique, the coverage of the lymph nodes
increased significantly to on average 98.2% (p ≤ 0.01
compared to HTF hh) while PTVp did not vary signifi-
cantly (p = 0.65 compared to HTF hh). The doses to the
OAR were comparable between the HTF without and
with sparing of the humeral head and the 6-field IMRT
technique (Table 2). The coverage of PTVn increased
when using VMAT to an average of 99.5% (p = 0.51
compared to IMRT and p ≤ 0.01 compared to HTF hh).
The conformity indices improved significantly for each
Table 1 Initial set of objectives used for the inverse optimization
Region of Interest Type Target (cGy) Volume (%) Weight gEUD
PTVp-Lungs-Skin07a Min DVH 4043 99 75
Max DVH 4470 1 1
Uniform Dose 4256 1
PTVn-Lungs-Skin07 Min DVH 4043 99 75
Max DVH 4430 1 1
Uniform Dose 4256 0.1
15_Ringtot_30b Max Dose 4256 5
Lungs Max EUD 700 1 1
Heart Max EUD 700 1 1
For 6-field IMRT and VMAT with
sparing of the humeral head:
10_Ring_10c Max Dose 3900 1
hh+10d Max Dose 3800 1
aPTVp excluding the lungs and the skin + 7 mm
bA ring at 15 mm distance from PTVtotal with a width of 30 mm, excluding the lungs and skin + 7 mm
cA ring at 10 mm distance from PTVtotal with a width of 10 mm, with the caudal border 1 cm below the sternoclavicular joint and excluding the skin + 7 mm
dHumeral head + 10 mm
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Fig. 2 Beam arrangement for the 6-field IMRT technique; a axial, b sagittal and c coronal view. Two high tangential fields (red) and four additional
fields (green). PTVp in red, PTVn in turquoise, contralateral breast in blue and humeral head + 10 mm in green










VMAT HTF hh – VMAT
p-value
PTVp V90% (%) 99.9 (99.7–100) ≤0.01 99.5 (95.6–100) 0.08 99.8 (99.2–100) ≤0.01 99.5 (98.8–99.9) 0.08
PTVp V95% (%) 97.8 (97.2–99.5) 0.02 97.2 (91.8–99.5) 0.65 97.3 (96.7–98.8) 0.09 97.1 (96.6–97.4) 0.14
PTVn V90% (%) 97.9 (96.6–99.3) ≤0.01 89.4 (73.3–98.7) ≤0.01 98.2 (91.3–99.9) 0.51 99.5 (98.2–99.9) ≤0.01
PTVn V95% (%) 86.5 (81.4–94.2) ≤0.01 73.6 (56.9–87.6) ≤0.01 91.1 (77.8–98.2) 0.05 95.4 (88.3–98.3) ≤0.01
CI95% 1.24 (1.04–1.41) ≤0.01 1.16 (1.01–1.29) ≤0.01 1.06 (0.93–1.18) ≤0.01 0.90 (0.77–1.06) ≤0.01
CI90% 1.49 (1.25–1.66) ≤0.01 1.41 (1.22–1.51) ≤0.01 1.33 (1.14–1.41) ≤0.01 1.09 (0.97–1.25) ≤0.01
Lungs Dmean (Gy) 4.8 (3.9–6.1) 0.02 4.7 (3.9–6.1) 0.33 4.8 (3.8–5.9) 0.24 5.2 (4.2–6.8) 0.17
Heart Dmean (Gy) 3.3 (1.7–6.2) ≤0.01 3.3 (1.6–6.1) ≤0.01 2.9 (1.6–5.7) 0.04 3.6 (2.0–5.7) 0.51
Contralat. breast Dmean (Gy) 0.7 (0.3–0.9) ≤0.01 0.6 (0.3–0.9) 0.02 0.6 (0.3–0.7) ≤0.01 2.3 (0.6–4.2) ≤0.01
hh+10 V40Gy (cc) 20.7 (0–66.9) ≤0.01 0.5 (0–1.2) 0.37 0.6 (0–1.8) 0.31 0.6 (0–1.3) 0.26
HTF High tangential fields, HTF hh HTF with sparing of the humeral head, CI95% Conformity index of the 95% isodose, CI90% Conformity index of the 90%
isodose, hh+10 humeral head + 10 mm. Values are averages with the range indicated in brackets. p-values are written in bold when statistical significance is
reached (p ≤ 0.0125)
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change in technique (Table 2). Note that CI were calcu-
lated for the total PTV, combining PTVp and PTVn.
However, the dose to the OAR increased as well when
using the VMAT technique. The mean dose to the
contralateral breast increased significantly from 0.7 Gy
with HTF and 0.6 Gy with HTF hh and 6-field IMRT to
2.3 Gy with VMAT (p ≤ 0.01 compared to IMRT and
HTF hh).
A single patient out of ten met the constraint for hh
+10 with HTF. This patient was also the only patient
that did not have an overlap between hh+10 and the
total PTV. The overlap was on average 2.1 cc (0–5.1 cc).
Examples of the dose distributions of all four tech-
niques can be found in Fig. 3.
Discussion
In case of elective breast radiotherapy including the
axillary levels I and II, we compared four planning
techniques and evaluated the coverage of the PTVs
and the OARs. We found that 6-field IMRT with
sparing of the humeral head resulted in the best
coverage of PTVp and PTVn while not increasing the
dose to the lungs, heart and contralateral breast com-
pared to HTF.
The coverage of PTVn was increased significantly
with the 6-field IMRT technique compared to the
HTF. Dogan et al. treated the whole breast and the
internal mammary node, supraclavicular and axillary
lymph nodes with a 6-field IMRT technique and
achieved a D95% of 50.2 ± 0.8 Gy to the axillary
lymph nodes with a prescription dose of 50 Gy in 25
fractions [14]. With a 2-field IMRT approach similar
to our HTF, this was 49.8 ± 0.8 Gy. However, sparing
of the humeral head was not achieved with these
techniques. In our study, the most optimal sparing of
the humeral head was achieved with the 6-field
IMRT, which is similar to their 6-field IMRT tech-
nique, and VMAT technique while still meeting the
constraints for lymph node coverage. Dogan et al.
mentioned treatment complexity as one of the factors
for choosing 2- and 4-field IMRT as optimal tech-
niques. Currently, treatment complexity (i.e. number
of IMRT beams) is no longer a limiting factor.
Alco et al. recorded a V95% of 94.4% (85.3–98.7%) in
level I and 90.1% (80.6–94.4%) in level II lymph nodes
with modified HTF [12]. The tangential fields were
modified to extend just until the inferior border of the
humeral head and the MLCs were manipulated to in-
clude the level I and II lymph nodes. Alco et al. did not
spare the humeral head. We found a lower PTVn V95%
with the two HTF techniques, but when using 6-field
IMRT and VMAT the V95% improved. With the more
Fig. 3 Dose distributions of a HTF, b HTF with sparing of the humeral head, c 6-field IMRT with sparing of the humeral head and d VMAT with
sparing of the humeral head. PTVp in red, PTVn in turquoise, contralateral breast in blue and humeral head + 10 mm in green. Isodose lines: red:
100%, yellow: 95% and orange: 90%
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advanced 6-field IMRT and VMAT technique including
sparing of the humeral head, our PTVn V95% was com-
parable to Alco et al. with IMRT and better than Alco et
al. with VMAT.
Ohashi et al. reported level I and II V90% of 97.6%
(96.0–99.2%) and 89.5% (84.2–93.2%) with modified
HTF [13]. Their HTF technique was similar to Alco et
al. and did also not spare the humeral head. In our
study, PTVn coverage with HTF is higher (average V90%
97.9%, range 96.6–99.3), but decreased to an inaccepta-
ble level when sparing the humeral head. Again, the
more advanced IMRT and VMAT techniques reached
the same or better coverage compared to Ohashi et al.
while sparing the humeral head.
Belkacemi et al. concluded that HTF did not result in
adequate coverage of the level I and II lymph nodes [11].
They extended the cranial border of the tangential fields
until the inferior border of the humeral head similar to
Ohashi et al. and Alco et al., but did not extend the pos-
terior field border. In our experience, the cranial and
posterior part of the lymph nodes can extend beyond
the caudal border of the humeral head in the tangential
fields and therefore be outside the treatment field. In
our study, the cranial and posterior border of the HTF
was based on the dimensions of PTVn and resulted in
sufficient PTVn coverage. PTVn coverage decreased sig-
nificantly when sparing the humeral head by closing the
MLC due to the overlap between PTV and hh+10; par-
ticularly a too low dose in level II (see Table 2 and
Fig. 3b).
Dogan et al. concluded that high doses in the heart
can be reduced with IMRT techniques while
maintaining excellent coverage of the breast and re-
gional nodes [14]. Schubert et al. [9] compared differ-
ent planning techniques for the whole breast and
reported the following OAR dose parameters with an
inverse IMRT technique: Dmean heart 1.9 ± 0.8 Gy
and Dmean contralateral breast 0.3 ± 0.1 Gy. With
tomotherapy, these parameters were 3.9 ± 1.3 Gy and
0.6 ± 0.1 Gy, respectively. We found slightly larger
average doses to the heart and contralateral breast
(Table 2) due to the increased treatment volume
when axillary lymph nodes are involved. When com-
paring the four techniques, the differences between
the mean dose to the heart and contralateral breast
are often statistically significant. However, the differ-
ences are very likely in most cases not clinically rele-
vant except for the increase in contralateral breast
dose when comparing IMRT and VMAT. Osman et
al. also found a similar increase in contralateral breast
dose when using VMAT (Dmean on average 2.7 Gy)
compared to forward planned IMRT (Dmean on aver-
age 0.7 Gy) when treating the breast, internal mam-
mary node and periclavicular lymph nodes [15].
When comparing these planning studies, it has to be
noted that lymph node contouring may have been based
on different contouring guidelines. The ESTRO guide-
line by Offersen et al. [7] focusses on the delineation of
level I—IV lymph nodes and has been used in this plan-
ning study. In addition, contouring is prone to variabil-
ities and even when the same guideline is followed, its
interpretation can vary [22]. A PRV of the humeral head
with a margin of 10 mm is defined by Offersen et al. [7],
but no dose constraints are indicated.
Fig. 4 Reduction of PTVn coverage (V90% and V95%) due to sparing of the humeral head when using high tangential fields
Surmann et al. Radiation Oncology  (2017) 12:22 Page 6 of 8
Data on the dose to the humeral head and sur-
rounding tissue during breast radiotherapy is scarce.
In our planning study we restricted the high dose to
hh+10. Dogan et al. based their constraint of a max-
imum dose of 40 Gy on their clinical experience with
head and neck cancer [14].
As there is no consensus yet which DVH parameters
for the humeral head PRV are clinically most relevant,
we have also recorded Dmin, Dmean, Dmax, D0.5cc,
D2%, D98% and V50% (see Appendix Table 3). Ideally,
this constraint should be based on data correlating the
change in shoulder mobility to the dose in the shoulder
tissue. To the best of our knowledge, there is no litera-
ture on a dose-effect relationship for the shoulder tissue
and the shoulder mobility. Delineation and dose assess-
ment of the shoulder muscles should be further investi-
gated but is outside the scope of this article.
Conclusion
The humeral head is rarely spared when using conven-
tional high tangential fields. It is not possible to spare
the humeral head with HTF without reducing lymph
node coverage of level I and II. The humeral head and
surrounding tissues can be spared with the 6-field IMRT
and VMAT technique without reducing PTVn coverage.
The 6-field IMRT technique does not increase the dose
to the OARs compared to HTF, while the VMAT tech-
nique leads to a higher dose in the contralateral breast.
Appendix
Influence of overlap between PRV and PTV on nodal PTV
coverage
We started a sub-analysis in which we investigated
whether it is possible to indicate which patients will
benefit from a more advanced technique and which pa-
tients would be treated properly with the standard of
high tangential fields. A more advanced technique with
multiple beams takes longer to plan and requires a larger
time slot at the treatment machine for delivery.
We determined the overlap between the total PTV
and the humeral head + 10 mm PRV (hh+10) in cc and
the reduction of PTVn coverage between HTF with and
without sparing of the humeral head.
The results of this sub-analysis are given in Fig. 4. The
overlap between PTVn and hh+10 was on average 2.1 cc
(0–5.1 cc). Sparing the humeral head by closing the
MLC in the HTF reduced PTVn V95% by 12.9% (0–
31.2%) and PTVn V90% by 8.4% (0–24.3%). It was ex-
pected that a larger overlap between the PTV and hh+10
will result in a large reduction of PTVn coverage since
excluding hh+10 from the tangential treatment fields
will also mean exclusion of the overlapping PTV. How-
ever, there was no correlation between the volume over-
lap of the PTV and hh+10 and the reduction in PTVn
dose between HTF and HTF hh (Fig. 4).
Based on the ten patients from our planning study, it
is not possible to determine a maximum value for the
overlap that will still result in proper treatment with
HTF while sparing the humeral head. All patients will be
treated with the more advanced technique to spare the
humeral head and maintain proper PTVn coverage.
Additional dose parameters for the humeral head + 10
mm PRV
The additional dose parameters that were scored for the
humeral head + 10 mm PRV can be found in Table 3.
Abbreviations
hh+10: Humeral head + 10 mm; HTF: High tangential fields; OAR: Organs at
risk; PRV: Planning risk volume; PTVn: Planning target volume of the level I
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Table 3 Dose parameters for the humeral head + 10 mm PRV
HTF HTF – HTF hh
p-value
HTF hh HTF hh – IMRT
p-value
IMRT IMRT – VMAT
p-value
VMAT HTF hh – VMAT
p-value
Dmin (Gy) 1.6 (0.8–3.2) ≤0.01 1.4 (0.8–2.1) 0.01 1.1 (0.5–1.8) 0.21 1.1 (0.4–1.9) 0.08
Dmean (Gy) 14.8 (3.8–27.8) ≤0.01 10.1 (3.8–15.5) 0.80 10.8 (2.8–19.7) 0.41 11.5 (2.6–19.9) 0.24
Dmax (Gy) 42.7 (38.2–44.6) ≤0.01 40.3 (38.2–41.9) 0.24 40.8 (38.5–42.3) 0.28 40.6 (38.1–42.2) 0.38
D0.5cc (Gy) 42.2 (36.8–43.9) ≤0.01 39.0 (34.6–40.7) 0.72 39.6 (36.2–41.2) 0.20 39.2 (34.8–40.7) 0.44
D2% (Gy) 40.9 (29.8–43.5) ≤0.01 36.2 (29.8–39.6) 0.26 37.3 (28.8–39.4) 0.17 36.9 (26.6–39.8) 0.92
D98% (Gy) 1.9 (0.9–3.7) ≤0.01 1.5 (0.8–2.3) ≤0.01 1.2 (0.5–2.1) 0.16 1.2 (0.5–2.1) ≤0.01
V50% (%) 28.6 (3.4–59.9) ≤0.01 15.6 (3.4–35.4) 0.11 23.8 (3.1–47.2) 0.38 25.9 (2.4–50.3) 0.08
HTF High tangential fields, HTF hh HTF with sparing of the humeral head. Values are averages with the range indicated in brackets. p-values are written in bold
when statistical significance is reached (p ≤ 0.0125)
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